GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006631 | Colorectum | AD | fatty acid metabolic process | 114/3918 | 390/18723 | 5.58e-05 | 9.44e-04 | 114 |
GO:0009410 | Colorectum | AD | response to xenobiotic stimulus | 128/3918 | 462/18723 | 2.69e-04 | 3.31e-03 | 128 |
GO:00066312 | Colorectum | MSS | fatty acid metabolic process | 95/3467 | 390/18723 | 2.20e-03 | 1.84e-02 | 95 |
GO:00094101 | Colorectum | MSS | response to xenobiotic stimulus | 110/3467 | 462/18723 | 2.36e-03 | 1.92e-02 | 110 |
GO:00066313 | Colorectum | FAP | fatty acid metabolic process | 81/2622 | 390/18723 | 1.43e-04 | 2.24e-03 | 81 |
GO:00094102 | Colorectum | FAP | response to xenobiotic stimulus | 87/2622 | 462/18723 | 2.15e-03 | 1.77e-02 | 87 |
GO:00066314 | Colorectum | CRC | fatty acid metabolic process | 65/2078 | 390/18723 | 5.30e-04 | 7.42e-03 | 65 |
GO:1903522 | Colorectum | CRC | regulation of blood circulation | 43/2078 | 256/18723 | 3.70e-03 | 3.12e-02 | 43 |
GO:00094103 | Colorectum | CRC | response to xenobiotic stimulus | 69/2078 | 462/18723 | 6.34e-03 | 4.61e-02 | 69 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CYP2J2 | SNV | Missense_Mutation | novel | c.283C>T | p.Pro95Ser | p.P95S | P51589 | protein_coding | tolerated(0.15) | benign(0.159) | TCGA-B6-A1KC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CYP2J2 | SNV | Missense_Mutation | novel | c.358N>G | p.Ile120Val | p.I120V | P51589 | protein_coding | tolerated(0.77) | benign(0.009) | TCGA-PL-A8LX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CYP2J2 | insertion | Frame_Shift_Ins | novel | c.732_733insTTCCCCAAAATTATAGG | p.Gln245PhefsTer16 | p.Q245Ffs*16 | P51589 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CYP2J2 | insertion | Nonsense_Mutation | novel | c.1123_1124insGGTGTGAGCCACTGCTTCTGACAGCTGTATAATTTATTAT | p.Ile375ArgfsTer11 | p.I375Rfs*11 | P51589 | protein_coding | | | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD |
CYP2J2 | deletion | Frame_Shift_Del | | c.1331_1356delNNNNNNNNNNNNNNNNNNNNNNNNNN | p.Gly444ValfsTer5 | p.G444Vfs*5 | P51589 | protein_coding | | | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
CYP2J2 | insertion | In_Frame_Ins | novel | c.1023_1024insAGTAGTTTTTCAACCCTTGCCCCACTCTCTCCTCCA | p.Ile341_Asp342insSerSerPheSerThrLeuAlaProLeuSerProPro | p.I341_D342insSSFSTLAPLSPP | P51589 | protein_coding | | | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
CYP2J2 | deletion | Frame_Shift_Del | novel | c.524delG | p.Gly175AspfsTer38 | p.G175Dfs*38 | P51589 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
CYP2J2 | SNV | Missense_Mutation | novel | c.1429G>A | p.Glu477Lys | p.E477K | P51589 | protein_coding | tolerated(0.21) | benign(0.285) | TCGA-C5-A3HD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
CYP2J2 | SNV | Missense_Mutation | | c.671C>T | p.Ser224Leu | p.S224L | P51589 | protein_coding | deleterious(0.01) | benign(0.41) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CYP2J2 | SNV | Missense_Mutation | | c.888N>A | p.Phe296Leu | p.F296L | P51589 | protein_coding | deleterious(0.03) | possibly_damaging(0.766) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | | terfenadine | TERFENADINE | 15861034 |
1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | | nabumetone | NABUMETONE | 19923256 |
1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | | thioridazine | THIORIDAZINE | 19923256 |
1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | | diclofenac | DICLOFENAC | 15861034 |
1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | inhibitor | 252827489 | | |
1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | | astemizole | ASTEMIZOLE | 15861034 |
1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | | albendazole | ALBENDAZOLE | 19923256 |
1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | inhibitor | 135651245 | TERFENADINE | |
1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | | danazol | DANAZOL | 19923256 |
1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | | mesoridazine | MESORIDAZINE | 19923256 |